Home › Funds › Stonepine Capital Management, LLC › CTMX
Stonepine Capital Management, LLC position in CTMX
CYTOMX THERAPEUTICS INC. · Health Care
Stonepine Capital Management, LLC reported holding 220,000 shares of CTMX (CYTOMX THERAPEUTICS INC.) in its Q3 2026 13F filing — a position valued at US$598K, representing 0.46% of its reported portfolio and ranking #43 among its reported holdings. Stonepine Capital Management, LLC has disclosed CTMX holdings in 4 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Stonepine Capital Management, LLC's CTMX position evolved
Stonepine Capital Management, LLC first disclosed a stake in CTMX in Q3 2025 at 125,000 shares (US$399K). The position peaked in Q1 2026 at 200,000 shares, worth US$940K. Across 4 filings, Stonepine Capital Management, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 220,000 shares valued at US$598K — an increase of 15,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 125.00K | $398.75K | New |
| Q1 2026 | 200.00K | $940.00K | New |
| Q2 2026 | 205.00K | $768.75K | Add |
| Q3 2026 | 220.00K | $598.40K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CTMX and 13F data
CTMX (CYTOMX THERAPEUTICS INC.) is a Health Care company. 42 other funds we track also report a position in CTMX — the largest reported positions include Kynam Capital Management, LP (US$81.4M), PERCEPTIVE ADVISORS LLC (US$39.1M), Venrock Adviser, LLC (US$18.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CTMX
- Kynam Capital Management, LP 21.70M sh · $81.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.44M sh · $39.15M · Q2 2026
- Venrock Adviser, LLC 4.98M sh · $18.68M · Q2 2026
- Elmind Capital, LP 4.55M sh · $17.06M · Q2 2026
- Nextech Invest Ltd. 4.45M sh · $16.69M · Q2 2026
- Eversept Partners, LP 3.56M sh · $13.34M · Q2 2026
- ADAR1 Capital Management, LLC 3.37M sh · $12.62M · Q2 2026
- Seven Fleet Capital Management LP 1.09M sh · $4.07M · Q2 2026
- Ally Bridge Group (NY) LLC 775.00K sh · $2.91M · Q2 2026
More on Stonepine Capital Management, LLC
FAQ
How long has Stonepine Capital Management, LLC held CTMX?
Stonepine Capital Management, LLC has disclosed CTMX holdings in 4 of the last 5 reported quarters, going back to Q3 2025.
What is Stonepine Capital Management, LLC's current position in CTMX?
As of Q3 2026, Stonepine Capital Management, LLC holds 220.00K shares of CTMX (CYTOMX THERAPEUTICS INC.), valued at $598.40K, representing 0.46% of its reported portfolio and ranking #43.
Has Stonepine Capital Management, LLC been buying or selling CTMX?
In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC increased its position in CTMX. The position peaked in Q1 2026 at 200.00K shares.
Which other funds hold CTMX?
Other major institutional holders of CTMX include Kynam Capital Management, LP, PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.